SAR444671 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia3

61. Autoimmune hemolytic anemia


Clinical trials : 137 Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-001671-16-DK
(EUCTR)
15/11/202116/07/2021Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemiaA multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Warm autoimmune hemolytic anemia
MedDRA version: 20.0;Level: PT;Classification code 10073785;Term: Autoimmune haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Rilzabrutinib
Product Code: SAR444671
INN or Proposed INN: Rilzabrutinib
Other descriptive name: PRN1008
Sanofi aventis recherche et developpementNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
25Phase 2United States;Spain;Denmark;United Kingdom;Italy;China
2EUCTR2021-001671-16-ES
(EUCTR)
08/10/202123/06/2021Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemiaA multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Warm autoimmune hemolytic anemia
MedDRA version: 20.0;Level: PT;Classification code 10073785;Term: Autoimmune haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Rilzabrutinib
Product Code: SAR444671
INN or Proposed INN: Rilzabrutinib
Other descriptive name: PRN1008
Sanofi aventis recherche et developpementNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
25Phase 2United States;Spain;Denmark;United Kingdom;Italy;China
3EUCTR2021-001671-16-IT
(EUCTR)
24/09/202112/10/2021Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warmautoimmune hemolytic anemiaA multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia - . Warm autoimmune hemolytic anemia
MedDRA version: 20.0;Level: PT;Classification code 10073785;Term: Autoimmune haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Rilzabrutinib
Product Code: [SAR444671]
INN or Proposed INN: Rilzabrutinib
Other descriptive name: PRN1008
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENTNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
25Phase 2United States;Spain;Denmark;United Kingdom;China;Italy